News Focus
News Focus
icon url

kund

10/21/24 10:08 AM

#471877 RE: Hosai #471876

No surprise here, Misleading does this regularly, and there's no guarantee of that oral presentation either.
icon url

frrol

10/21/24 10:45 AM

#471878 RE: Hosai #471876

Our poster has been removed. On the one hand, oral communications are more important than posters. On the other, our poster was for "SIGMAR1 gene variant analysis", which was an important and still undisclosed endpoint and the last big question mark from our 2b/3. The communication title doesn't mention it, so we're now in the dark on whether we'll be getting it at CTAD. Who knows. Is the paper about to be published in the next few weeks, requiring the poster withdrawal? Will the variant analysis be included in the talk anyway? Let's see what CTAD brings. Btw the company should be announcing our CTAD attendance pretty soon.
icon url

williamssc

10/21/24 10:56 AM

#471881 RE: Hosai #471876

7:30 a.m. POSTER WALKING TOUR
9:00 a.m. LB9 - Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation

Marwan Sabbagh
, Juan-Carlos Lopez-Talavera
, Kun Jin
, William Chezem
, Christopher Missling
Barrow Neurological Institute - Phoenix (United States),
Anavex - New York (United State
Page 15
https://www.ctad-alzheimer.com/files/files/PROGRAM_CTAD2024_WEB%20OCTOBER%2018.pdf
Thanks for the link Hosai